PT1408966E - Combinações farmacêuticas sinergísticas para a prevenção ou tratamento da diabetes - Google Patents

Combinações farmacêuticas sinergísticas para a prevenção ou tratamento da diabetes Download PDF

Info

Publication number
PT1408966E
PT1408966E PT02751454T PT02751454T PT1408966E PT 1408966 E PT1408966 E PT 1408966E PT 02751454 T PT02751454 T PT 02751454T PT 02751454 T PT02751454 T PT 02751454T PT 1408966 E PT1408966 E PT 1408966E
Authority
PT
Portugal
Prior art keywords
prevention
treatment
diabetes
pharmaceutical combinations
synergistic pharmaceutical
Prior art date
Application number
PT02751454T
Other languages
English (en)
Portuguese (pt)
Inventor
Zoltan Szilvassy
Gyoergy Rabloczky
Peter Literati Nagy
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Publication of PT1408966E publication Critical patent/PT1408966E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
PT02751454T 2001-07-17 2002-07-10 Combinações farmacêuticas sinergísticas para a prevenção ou tratamento da diabetes PT1408966E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére

Publications (1)

Publication Number Publication Date
PT1408966E true PT1408966E (pt) 2008-05-02

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02751454T PT1408966E (pt) 2001-07-17 2002-07-10 Combinações farmacêuticas sinergísticas para a prevenção ou tratamento da diabetes

Country Status (21)

Country Link
US (2) US7635674B2 (enExample)
EP (1) EP1408966B1 (enExample)
JP (1) JP4598390B2 (enExample)
KR (1) KR100920560B1 (enExample)
CN (1) CN1270713C (enExample)
AT (1) ATE386523T1 (enExample)
AU (1) AU2002354884B2 (enExample)
BR (1) BR0210744A (enExample)
CA (2) CA2682251A1 (enExample)
CY (1) CY1107939T1 (enExample)
DE (1) DE60225143T2 (enExample)
DK (1) DK1408966T3 (enExample)
ES (1) ES2300460T3 (enExample)
IL (2) IL159412A0 (enExample)
MX (1) MXPA04000324A (enExample)
NO (1) NO20040153L (enExample)
NZ (1) NZ531155A (enExample)
PL (1) PL205826B1 (enExample)
PT (1) PT1408966E (enExample)
RU (1) RU2311907C2 (enExample)
WO (1) WO2003007951A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1807093A2 (en) * 2004-10-13 2007-07-18 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
ZA200902761B (en) * 2006-11-02 2010-07-28 N Gene Res Lab Inc A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2355680T3 (es) * 2006-11-02 2011-03-30 N-Gene Research Laboratories Inc. Reducción del sobrepeso o de la obesidad.
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7753949B2 (en) * 2007-02-23 2010-07-13 The Trustees Of The University Of Pennsylvania Valve prosthesis systems and methods
AR067557A1 (es) 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
US8277845B2 (en) * 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
JP5951752B2 (ja) 2011-04-13 2016-07-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｐｔｐ１ｂ発現のアンチセンス調節
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
MX2019015475A (es) 2017-06-30 2020-02-19 Univ California Composiciones y metodos para modular el crecimiento del cabello.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021242916A1 (en) * 2020-05-27 2021-12-02 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
US7635674B2 (en) 2009-12-22
KR20040029371A (ko) 2004-04-06
IL159412A0 (en) 2004-06-01
CA2452558A1 (en) 2003-01-30
CA2452558C (en) 2009-12-22
PL205826B1 (pl) 2010-05-31
ATE386523T1 (de) 2008-03-15
CA2682251A1 (en) 2003-01-30
ES2300460T3 (es) 2008-06-16
PL364662A1 (en) 2004-12-13
KR100920560B1 (ko) 2009-10-08
AU2002354884A2 (en) 2003-03-03
BR0210744A (pt) 2004-07-20
NO20040153L (no) 2004-03-16
JP4598390B2 (ja) 2010-12-15
AU2002354884B2 (en) 2007-10-18
DK1408966T3 (da) 2008-06-16
DE60225143D1 (de) 2008-04-03
WO2003007951A1 (en) 2003-01-30
US8048873B2 (en) 2011-11-01
IL159412A (en) 2009-09-22
RU2004105149A (ru) 2005-04-20
RU2311907C2 (ru) 2007-12-10
JP2004537550A (ja) 2004-12-16
EP1408966A1 (en) 2004-04-21
CY1107939T1 (el) 2013-09-04
EP1408966B1 (en) 2008-02-20
DE60225143T2 (de) 2009-02-12
NZ531155A (en) 2005-07-29
MXPA04000324A (es) 2004-07-23
CN1531433A (zh) 2004-09-22
US20070015687A1 (en) 2007-01-18
US20100048627A1 (en) 2010-02-25
CN1270713C (zh) 2006-08-23

Similar Documents

Publication Publication Date Title
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
PT1408966E (pt) Combinações farmacêuticas sinergísticas para a prevenção ou tratamento da diabetes
WO1999063826A3 (de) Mittel zur bekämpfung von pflanzenschädlingen
DZ3312A1 (fr) Compositions pharmaceutiques contenant des derives d&#39;azetidine, les nouveaux derives d&#39;azetidine et leur preparation
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU6327694A (en) Fungicidal compositions
CA2367017A1 (en) Inhibitors of impdh enzyme
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004779A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
DE60112330D1 (en) Pyrazolopyridinderivate
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
WO2002062322A3 (en) Glycine betaine and its use as anti-hemorrhagic agent
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
AU2002248531A1 (en) Pyrazolopyriadine derivatives
AU2001256727A1 (en) Preventive or therapeutic drugs for cancers containing cyanidin compounds as theactive ingredient
UA81608C2 (ru) Синергическая фармацевтическая комбинация для профилактики или лечения диабета
IL159841A0 (en) Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
PL314794A1 (en) Crystalline polymorphous form of (s,s,s)-n-(1-[2-carbocy-3-(n2-mezilolysilamino)propyl]-1-cyclopentylocabonyl)thyrosine
NO983217D0 (no) Terapeutiske anti-astmamidler som inneholder selenforbindeler
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient